文献速递心力衰竭与心肌病

缺铁性心力衰竭患者静脉羧基麦芽糖铁的疗效:个体患者数据荟萃分析

Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.
PubMed 文献 · Eur Heart J · 2023-01-01

该荟萃分析纳入3项随机安慰剂对照试验共4501例缺铁性心力衰竭成人患者,评估静脉羧基麦芽糖铁(FCM)对住院和死亡的影响。疗效似源于住院率降低而非生存改善。

要点

  • 静脉FCM可显著降低心血管住院与心血管死亡复合终点风险。
  • 总心衰住院与心血管死亡复合终点呈下降趋势但未达统计学显著。
  • 治疗效应主要来自住院率降低,对死亡率无明显影响,安全性良好。

核心结论

  • 在缺铁性射血分数降低的心力衰竭患者中,静脉FCM与心衰住院和心血管住院风险显著降低相关,但对死亡率无明显影响。

研究设计与样本

  • 随机、安慰剂对照FCM试验的个体患者数据荟萃分析,纳入缺铁性心力衰竭成人患者且随访≥52周。

主要发现

  • 共纳入3项FCM试验、4501例患者。
  • 治疗效应似源于住院率降低而非生存改善,安全性良好且耐受性好。

临床怎么用

  • 对缺铁性射血分数降低的心力衰竭患者,可考虑静脉FCM以降低心衰及心血管住院风险;对生存获益不应抱有过高预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Whereas a beneficial effect of intravenous ferric carboxymaltose (FCM) on symptoms and exercise capacity among patients with iron deficiency and heart failure (HF) has been consistently demonstrated, the effects of treatment on clinical events remain the subject of research. This meta-analysis aimed to characterize the effects of FCM therapy on hospitalizations and mortality. METHODS: Patient-level data from randomized, placebo-controlled FCM trials including adults with HF and iron deficiency with ≥52 weeks follow-up were analysed. The co-primary efficacy endpoints were (i) composite of total/recurrent cardiovascular hospitalizations and cardiovascular death and (ii) composite of total HF hospitalizations and cardiovascular death, through 52 weeks. Key secondary endpoints included individual composite endpoint components. Event rates were analysed using a negative binomial model. Treatment-emergent adverse events were also examined. RESULTS: Three FCM trials with a total of 4501 patients were included. Ferric carboxymaltose was associated with a significantly reduced risk of co-primary endpoint 1 (rate ratio 0.86; 95% confidence interval 0.75-0.98; P = .029; Cochran Q: 0.008), with a trend towards a reduction of co-primary endpoint 2 (rate ratio 0.87; 95% confidence interval 0.75-1.01; P = .076; Cochran Q: 0.024). Treatment effects appeared to result from reduced hospitalization rates, not improved survival. Treatment appeared to have a good safety profile and was well tolerated. CONCLUSIONS: In iron-deficient patients with HF with reduced left ventricular ejection fraction, intravenous FCM was associated with significantly reduced risk of hospital admissions for HF and cardiovascular causes, with no apparent effect on mortality.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Ponikowski P, Mentz RJ, Hernandez AF, et al. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Eur Heart J. 2023. PMID: 37632415. doi:10.1093/eurheartj/ehad586

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。